Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy (Q35705221)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 January 2012

Language	Label	Description	Also known as
English	Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy	scientific article published on 10 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

18

object named as

Marc Buyse

0 references

20

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Maria Litwiniuk

14

object named as

Maria Litwiniuk

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Wojciech Biernat

2

object named as

Wojciech Biernat

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Piotr Jan Wysocki

object named as

Piotr Wysocki

10

0 references

Renata Duchnowska

1

object named as

Renata Duchnowska

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Bogumiła Czartoryska-Arłukowicz

9

object named as

Bogumiła Czartoryska-Arłukowicz

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

4

object named as

Jeff Sperinde

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Barbara Szostakiewicz

3

object named as

Barbara Szostakiewicz

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6

object named as

Mojgan Haddad

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Fanny Piette

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Agnes Paquet

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Yolanda Lie

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Tomasz Jankowski

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Barbara Radecka

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Małgorzata Foszczynska-Kłoda

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sylwia Debska

15

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jodi Weidler

16

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Weidong Huang

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Michael Bates

19

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

10 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

26-35

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Receptor conversion in distant breast cancer metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Genes that mediate breast cancer metastasis to the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Metastasis: from dissemination to organ-specific colonization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Subtypes of breast cancer show preferential site of relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Breast cancer subtypes and survival in patients with brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

12 July 2018

Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

HER-2/neu Status in Breast Cancer Metastases to the Central Nervous System

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Central nervous system metastasis from breast carcinoma. Autopsy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3267818

25 September 2018

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HER-2 Positive Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in CSF

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22234627

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1634/THEONCOLOGIST.2011-0212

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35705221&oldid=2119130672"